Terns Pharmaceuticals (TERN) Competitors

Terns Pharmaceuticals (NASDAQ:TERN) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Does the media prefer TERN or OCUL?

In the previous week, Ocular Therapeutix had 12 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 17 mentions for Ocular Therapeutix and 5 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.61 beat Ocular Therapeutix's score of 0.17 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Terns Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings & valuation, TERN or OCUL?

Terns Pharmaceuticals has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terns Pharmaceuticals	N/A	N/A	-$88.85M	-$1.04	-6.24
Ocular Therapeutix	$63.72M	34.13	-$193.51M	-$1.28	-9.77

Is TERN or OCUL more profitable?

Terns Pharmaceuticals has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Terns Pharmaceuticals' return on equity of -27.35% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Terns Pharmaceuticals	N/A	-27.35%	-26.18%
Ocular Therapeutix	-382.51%	-71.92%	-49.36%

Do analysts prefer TERN or OCUL?

Terns Pharmaceuticals presently has a consensus target price of $15.63, suggesting a potential upside of 140.76%. Ocular Therapeutix has a consensus target price of $17.20, suggesting a potential upside of 37.60%. Given Terns Pharmaceuticals' higher probable upside, research analysts clearly believe Terns Pharmaceuticals is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ocular Therapeutix	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, TERN or OCUL?

Terns Pharmaceuticals has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in TERN or OCUL?

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Terns Pharmaceuticals beats Ocular Therapeutix on 9 of the 15 factors compared between the two stocks.